Enhertu to demonstrate a significant survival benefit vs. chemotherapy

Shilpa Medicare introduces cancer drug Capecitabine 1000 MG dispersible tablet

The product is backed by required scientific proof and comparative bioequivalence studies

Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast

Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning

Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial

Results reinforce commitment to next-generation oral SERD development programme

CAPED Trust and AstraZeneca India launch ‘Ganga Godavari Cancer Screening Program’ in Mathura

In the next six months, the program aims to screen 4,000 women from underprivileged communities in and around Mathura

Novartis unveils new focused strategy

Transformation to pure-play Innovative Medicines company nears completion

Medical devices market in Singapore to reach $3.5 billion in 2022, forecasts GlobalData

Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments

DCGI approves AstraZeneca 's Olaparib film-coated tablets

Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer

European Medicines Agency accepts Menarini’s application for Elacestrant

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union

Sanofi updates on amcenestrant clinical development program

The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial